Anti B7 H3 CAR-T-cell therapy (BoYuan RunSheng Pharma)(Anti B7 H3 CAR-T-cell therapy (BoYuan RunSheng Pharma)) - 药物靶点：CD276_在研适应症：复发性胶质母细胞瘤_专利_临床

概要

基本信息

药物类型

自体CAR-T

别名

AntiB7H3 CART cell therapy BoYuan RunSheng Pharma、B7H3 CART、BP102 BoYuan RunSheng Pharma

+ [2]

靶点

CD276

作用机制

CD276抑制剂(CD276抗原抑制剂)、基因转移、T淋巴细胞替代物

治疗领域

肿瘤神经系统疾病其他疾病

在研适应症

复发性胶质母细胞瘤

非在研适应症-

原研机构

在研机构

非在研机构-

最高研发阶段临床1/2期

首次获批日期-

最高研发阶段(中国)临床1/2期

特殊审评-

登录后查看时间轴

关联

2

项与 Anti B7 H3 CAR-T-cell therapy (BoYuan RunSheng Pharma) 相关的临床试验

NCT04077866 / Recruiting临床1/2期IIT

B7-H3-Targeted Chimeric Antigen Receptor (CAR) T Cells in Treating Patients With Recurrent or Refractory Glioblastoma

This is a randomized, parallel-arm, phase I/II study to evaluate the safety and efficacy of B7-H3 CAR-T in between Temozolomide cycles comparing to Temozolomide alone in treating patients with glioblastoma that has come back or does not respond to the standard treatment. The antigen B7-H3 is highly expressed in glioblastoma of a subset of patients. B7-H3 CAR-T, made from isolated patient peripheral blood mononuclear cells, can specifically attack patient glioblastoma cells that expressing B7-H3.

开始日期2023-06-01

申办/合作机构

浙江大学医学院附属第二医院

[+3]

NCT04385173 / Recruiting临床1期IIT

A Pilot Study of Chimeric Antigen Receptor (CAR) T Cells Targeting B7-H3 Antigen in Treating Patients With Recurrent and Refractory Glioblastoma

This is a pilot phase I study to evaluate the safety and efficacy on B7-H3 CAR-T in between Temozolomide cycles in treating patients with glioblastoma that has come back or does not respond to the standard treatment. The antigen B7-H3 is highly expressed in glioblastoma of a subset of patients. B7-H3 CAR-T, made from isolated patient peripheral blood mononuclear cells, can specifically attack patient glioblastoma cells that expressing B7-H3.

开始日期2022-12-01

申办/合作机构

浙江大学医学院附属第二医院

[+1]

100 项与 Anti B7 H3 CAR-T-cell therapy (BoYuan RunSheng Pharma) 相关的临床结果

登录后查看更多信息

100 项与 Anti B7 H3 CAR-T-cell therapy (BoYuan RunSheng Pharma) 相关的转化医学

登录后查看更多信息

100 项与 Anti B7 H3 CAR-T-cell therapy (BoYuan RunSheng Pharma) 相关的专利（医药）

登录后查看更多信息

2

项与 Anti B7 H3 CAR-T-cell therapy (BoYuan RunSheng Pharma) 相关的文献（医药）

2022-09-01·Molecular Therapy - Oncolytics

A novel anti-B7-H3 chimeric antigen receptor from a single-chain antibody library for immunotherapy of solid cancers

Article

作者: Ferry, Gabrielle ; Himoudi, Nourredine ; Chester, Kerry ; Parienti, Lara ; Rota, Enrique Miranda ; Anderson, John ; Gavriil, Artemis ; Birley, Kathleen ; Flutter, Barry ; Vitali, Alice ; Alonso-Ferrero, Maria ; Leboreiro-Babe, Clara ; Buschhaus, Magdalena ; Hopwood, Lee

B7-H3 (CD276) has emerged as a target for cancer immunotherapy by virtue of consistent expression in many malignancies, relative absence from healthy tissues, and an emerging role as a driver of tumor immune inhibition. Recent studies have reported B7-H3 to be a suitable target for chimeric antigen receptor-modified T cell (CAR-T) therapy using CARs constructed from established anti-B7-H3 antibodies converted into single-chain Fv format (scFv). We constructed and screened binders in an scFv library to generate a new anti-B7-H3 CAR-T with favorable properties. This allowed access to numerous specificities ready formatted for CAR evaluation. Selected anti-human B7-H3 scFvs were readily cloned into CAR-T and evaluated for anti-tumor reactivity in cytotoxicity, cytokine, and proliferation assays. Two binders with divergent complementarity determining regions were found to show optimal antigen-specific cytotoxicity and cytokine secretion. One binder in second-generation CD28-CD3ζ CAR format induced sustained in vitro proliferation on repeat antigen challenge. The lead candidate CAR-T also demonstrated in vivo activity in a resistant neuroblastoma model. An empirical approach to B7-H3 CAR-T discovery through screening of novel scFv sequences in CAR-T format has led to the identification of a new construct with sustained proliferative capacity warranting further evaluation.

Frontiers in Oncology

Case report: B7-H3 CAR-T therapy partially controls tumor growth in a basal cell carcinoma patient

作者: Zhu, Dingheng ; Huang, Taoyuan ; Wen, Wei ; Ding, Wen ; Zhou, Zhao ; Liang, Yunsheng ; Li, Guangchao ; Chen, Rongyi ; Luo, Min ; He, Renliang ; Ren, Junnan ; Hu, Gang ; Zheng, Yongwei

B7-H3 is over-expressed in multiple types of solid tumors, making it an ideal target for chimeric antigen receptor (CAR)-T therapy. Here, we first report a case of multiple basal cell carcinoma (BCC) patient treated with humanized monoclonal anti-B7-H3 CAR-T cells through direct intratumoral injection. After three dose-escalated injections, the lesion in the abdomen decreased by 40% in volume, shrank from bulging to flat, but was not eradicated completely. The large lesion in the forehead became dry from original ulcer and bleeding. The adverse events observed were itching, myalgia, and redness. Immunohistochemistry analysis demonstrated that B7-H3-positive tumor cells and B7-H3 expression intensity were reduced after injections of CAR-T cells. The number of infiltrating CD3 T cells increased significantly but mainly located outside the tumor region. Subsequently, high levels of TGF-β in the tumor area were observed, suggesting that solid tumor microenvironment may hinder the infiltration and effect of CAR-T cells. In summary, in this particular case report, intratumoral injection of B7-H3 CAR-T cells partially controls tumor growth in the BCC patient with minor adverse events. The efficacy and safety of B7-H3 CAR-T therapy need to be further investigated with a larger cohort of patients. Although only one clinical case is reported here, the anti-B7-H3 CAR-T cell therapy should be considered as a treatment option for solid tumors in the future. This clinical trial was registered at the Chinese Clinical Trial Registry (www.chictr.org.cn) with registration number ChiCTR2100044386.

100 项与 Anti B7 H3 CAR-T-cell therapy (BoYuan RunSheng Pharma) 相关的药物交易

登录后查看更多信息